慢性肾病的检测、分期与治疗在心血管疾病预防中的作用
本文综述了慢性肾病(CKD)的检测、分期与治疗在心血管疾病预防中的关键作用。CKD定义为肾小球滤过率低于60 mL/min/1.73 m2和/或尿白蛋白与肌酐比值大于30 mg/g(3 mg/mmol),全球约10%人口患病。CKD患者心血管事件风险显著增高,但检测率很低。文章强调需同时检测估算肾小球滤过率和白蛋白尿以正确分期并增强心血管风险分层,从而优先识别可从预防干预中获益的高危患者,并讨论了CKD检测在启动心肾保护治疗(如SGLT2抑制剂)中的核心作用及克服检测障碍的策略。
要点
- CKD定义为eGFR<60 mL/min/1.73 m2和/或UACR>30 mg/g(3 mg/mmol)。
- CKD患者心血管事件风险高,但检测率低,高危人群也应加强筛查。
- 同时检测eGFR和白蛋白尿有助于CKD分期和心血管风险分层。
核心结论
- CKD检测与分期应整合到心血管疾病预防中,以改善风险分层并指导心肾保护治疗。
研究设计与样本
- 综述,描述了CKD检测、分期和治疗在心血管疾病预防中的作用。
主要发现
- 全球约10%人口患有CKD。
- CKD患者心血管事件风险显著增高,多数患者更可能发生心血管事件而非进展至终末期肾病。
- 当前CKD检测率很低,即使在糖尿病、高血压和心血管疾病等高危人群中也是如此。
关键数值与推荐
- CKD定义为肾小球滤过率低于60 mL/min/1.73 m2和/或尿白蛋白与肌酐比值大于30 mg/g(3 mg/mmol)。
临床怎么用
- 在高危人群中同时检测估算肾小球滤过率和白蛋白尿以分期CKD并增强心血管风险分层。
- 利用CKD检测和分期优先识别可从心血管预防干预中获益的高危患者。
- CKD检测和分期是启动心肾保护治疗(如SGLT2抑制剂)的核心。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Globally, nearly 10% of the population has chronic kidney disease (CKD), defined as a glomerular filtration rate less than 60 mL/min/1.73 m2 and/or a urinary albumin to creatinine ratio greater than 30 mg/g (3 mg/mmol). Persons with CKD have a substantially high risk of cardiovascular disease. Indeed, most persons with CKD are far more likely to develop a cardiovascular event than to progress to end-stage kidney disease. Although early detection and staging of CKD could help prevent its cardiovascular consequences, current rates of testing for CKD are very low, even among high-risk populations such as persons with diabetes, hypertension and cardiovascular disease. In this review, we first describe the need to test for both estimated glomerular filtration rate and albuminuria among persons at high risk of CKD in order to properly stage CKD and enhance cardiovascular risk stratification. We then discuss how detection and staging for CKD could help prioritise patients at high risk of atherosclerotic cardiovascular disease and heart failure who could derive the largest benefit from cardiovascular preventive interventions. In addition, we discuss the central role of CKD detection and staging in the initiation of cardiorenal preventive therapies, such as the sodium-glucose cotransporter 2 inhibitors, which have shown overwhelming evidence of cardiorenal protection. We conclude by discussing strategies to overcome historical barriers to CKD detection and treatment.
引用
- Lamprea-Montealegre JA, Shlipak MG, Estrella MM, et al. Chronic kidney disease detection, staging and treatment in cardiovascular disease prevention. Heart. 2021. PMID: 33568433. doi:10.1136/heartjnl-2020-318004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。